Printed from Voxsanity (voxsanity.com.au) — NCT06973187 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have a confirmed diagnosis of CLL (chronic lymphocytic leukemia) or SLL (small lymphocytic lymphoma) that requires treatment, based on 2018 international guidelines.
People whose CLL/SLL has come back or stopped responding to previous treatment that included a specific type of medication called a covalent BTK inhibitor (a targeted cancer drug).
People with SLL must have at least one enlarged lymph node larger than 1.5 cm that can be measured by CT or MRI scan.
Who may not be able to join:
People who have a related blood cancer called prolymphocytic leukemia, or who have had or are suspected of having a condition called Richter's transformation (where CLL/SLL changes into a more aggressive cancer).
People who have a known bleeding disorder, such as hemophilia A, hemophilia B, or von Willebrand disease, or who have had serious unexplained bleeding that required a blood transfusion or medical treatment.
People who have had a stroke or bleeding in the brain within the 6 months before starting the study drug.
People who have previously been treated with a BTK protein degrader or a non-covalent BTK inhibitor (a different type of targeted cancer drug than the one required for entry).
People whose CLL/SLL has spread to the brain, spinal cord, or surrounding fluid or tissue, as confirmed by imaging, lab testing, or biopsy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Study Director, BeOne Medicines
Concord Repatriation General Hospital, Concord, New South Wales
St George Private Hospital, Kogarah, New South Wales
Westmead Private Hospital, Westmead, New South Wales
Pindara Private Hospital, Benowa, Queensland
Sunshine Coast Hospital and Health Service, Birtinya, Queensland
John Flynn Private Hospital, Tugun, Queensland
Flinders Medical Centre, Bedford PK, South Australia
St Vincents Hospital Melbourne, Fitzroy, Victoria
Peninsula Private Hospital, Frankston, Victoria
Austin Health, Heidelberg, Victoria
Cabrini Hospital Malvern, Malvern, Victoria
Peter Maccallum Cancer Centre, Melbourne, Victoria
The Alfred Hospital, Melbourne, Victoria
Linear Clinical Research, Nedlands, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06973187
Sponsor: BeOne Medicines
Phase: Phase 3
Status: Recruiting
Condition: Lymphoma
Trial contact: 1-877-828-5568
More information: https://clinicaltrials.gov/study/NCT06973187
Eligibility summary (AI generated)
Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have a confirmed diagnosis of CLL (chronic lymphocytic leukemia) or SLL (small lymphocytic lymphoma) that requires treatment, based on 2018 international guidelines.
People whose CLL/SLL has come back or stopped responding to previous treatment that included a specific type of medication called a covalent BTK inhibitor (a targeted cancer drug).
People with SLL must have at least one enlarged lymph node larger than 1.5 cm that can be measured by CT or MRI scan.
Who may not be able to join:
People who have a related blood cancer called prolymphocytic leukemia, or who have had or are suspected of having a condition called Richter's transformation (where CLL/SLL changes into a more aggressive cancer).
People who have a known bleeding disorder, such as hemophilia A, hemophilia B, or von Willebrand disease, or who have had serious unexplained bleeding that required a blood transfusion or medical treatment.
People who have had a stroke or bleeding in the brain within the 6 months before starting the study drug.
People who have previously been treated with a BTK protein degrader or a non-covalent BTK inhibitor (a different type of targeted cancer drug than the one required for entry).
People whose CLL/SLL has spread to the brain, spinal cord, or surrounding fluid or tissue, as confirmed by imaging, lab testing, or biopsy.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
BeOne Medicines
Registry
ClinicalTrials.gov
Start date
4 September 2025
Est. completion
17 April 2028
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇳 China
🇫🇷 France
🇩🇪 Germany
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇲🇽 Mexico
🇳🇱 Netherlands
🇳🇿 New Zealand
🇵🇱 Poland
Puerto Rico
🇷🇴 Romania
🇸🇬 Singapore
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
🇬🇧 United Kingdom
🇺🇸 United States
14 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS) per Independent Review Committee (IRC)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.